Next Article in Journal
Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma
Next Article in Special Issue
Immunotherapy for Management of Thymic Epithelial Tumors: A Double-Edged Sword
Previous Article in Journal
Quality Assessment of a Large Multi-Center Flow Cytometric Dataset of Acute Myeloid Leukemia Patients—A EuroFlow Study
Previous Article in Special Issue
The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug?
 
 
Review

Article Versions Notes

Cancers 2022, 14(8), 2013; https://doi.org/10.3390/cancers14082013
Action Date Notes Link
article pdf uploaded. 15 April 2022 15:20 CEST Version of Record https://www.mdpi.com/2072-6694/14/8/2013/pdf-vor
article xml file uploaded 18 April 2022 04:05 CEST Original file -
article xml uploaded. 18 April 2022 04:05 CEST Update https://www.mdpi.com/2072-6694/14/8/2013/xml
article pdf uploaded. 18 April 2022 04:05 CEST Updated version of record https://www.mdpi.com/2072-6694/14/8/2013/pdf
article html file updated 18 April 2022 04:07 CEST Original file -
article html file updated 2 August 2022 19:13 CEST Update https://www.mdpi.com/2072-6694/14/8/2013/html
Back to TopTop